These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26631615)

  • 1. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
    Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy of
    Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T
    Clin Cancer Res; 2021 Mar; 27(5):1438-1451. PubMed ID: 33310889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
    Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
    Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
    Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
    Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
    Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
    Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
    Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
    Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
    Berthon C; Raffoux E; Thomas X; Vey N; Gomez-Roca C; Yee K; Taussig DC; Rezai K; Roumier C; Herait P; Kahatt C; Quesnel B; Michallet M; Recher C; Lokiec F; Preudhomme C; Dombret H
    Lancet Haematol; 2016 Apr; 3(4):e186-95. PubMed ID: 27063977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
    Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
    J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.